Dermata Therapeutics, Inc. (NASDAQ: DRMAW) shares are trading higher in Thursday’s after-hours session after the company announced the issuance of a new patent in Japan for its DMT410 program for the treatment of hyperhidrosis. What To Know: The announcement of the patent was made Thursday after market close, making it Dermata’s first patent issued for DMT410. The program leverages the company’s Spongilla technology to topically deliver botulinum toxin in treating the condition. It was also noted there are talks of partnership prospects that would further the development of DMT410. “We believe…